The present and future burden of urinary bladder cancer in the world, World Journal of Urology, vol.102, issue.2, pp.289-93, 2009. ,
DOI : 10.1007/s00345-009-0383-3
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials, European Urology, vol.49, issue.3, pp.466-471, 2006. ,
DOI : 10.1016/j.eururo.2005.12.031
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients, Journal of Clinical Oncology, vol.19, issue.3, pp.666-75, 2001. ,
DOI : 10.1200/JCO.2001.19.3.666
Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium, The Journal of Urology, vol.176, issue.6, pp.2414-2436, 2006. ,
DOI : 10.1016/j.juro.2006.08.004
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium, The Lancet Oncology, vol.11, issue.9, pp.861-70, 2010. ,
DOI : 10.1016/S1470-2045(10)70086-3
The insulin and insulin-like growth factor receptor family in neoplasia: an update, Nature Reviews Cancer, vol.20, issue.3, pp.159-69, 2012. ,
DOI : 10.1200/JCO.2002.06.140
Disrupting insulin-like growth factor signaling as a potential cancer therapy, Molecular Cancer Therapeutics, vol.6, issue.1, pp.1-12, 2007. ,
DOI : 10.1158/1535-7163.MCT-06-0080
Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy, Urology, vol.83, issue.6, pp.1444-1441, 2014. ,
DOI : 10.1016/j.urology.2014.01.028
The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer, BJU International, vol.62, issue.6, pp.1396-401, 2007. ,
DOI : 10.1021/mp060001j
The Insulin-Like Growth Factor Receptor I Promotes Motility and Invasion of Bladder Cancer Cells through Akt- and Mitogen-Activated Protein Kinase-Dependent Activation of Paxillin, The American Journal of Pathology, vol.176, issue.6 ,
DOI : 10.2353/ajpath.2010.090904
Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells, PLoS ONE, vol.285, issue.6, p.40148, 2012. ,
DOI : 10.1371/journal.pone.0040148.s002
Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder, BJU International, vol.52, issue.5, pp.694-701, 2009. ,
DOI : 10.1172/JCI200421358
Targeting IGF-1R: at a crossroad, Oncology, vol.25, issue.6, pp.535-541, 2011. ,
Regional copy number???independent deregulation of transcription in cancer, Nature Genetics, vol.12, issue.12, pp.1386-96, 2006. ,
DOI : 10.1152/physiolgenomics.00116.2002
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, vol.19, issue.2, pp.185-93, 2003. ,
DOI : 10.1093/bioinformatics/19.2.185
Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data, Nucleic Acids Research, vol.33, issue.20, p.175, 2005. ,
DOI : 10.1093/nar/gni179
PI3K/AKT pathway activation in bladder carcinogenesis, International Journal of Cancer, vol.27, issue.8, pp.1776-84, 2014. ,
DOI : 10.1038/onc.2008.241
URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.28518/pdf
In vivo antitumor activity of NVP-AEW541???A novel, potent, and selective inhibitor of the IGF-IR kinase, Cancer Cell, vol.5, issue.3, pp.231-240, 2004. ,
DOI : 10.1016/S1535-6108(04)00051-0
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.53, issue.7391, pp.603-610, 2012. ,
DOI : 10.1002/pbc.20697
Linear Models for Microarray Data Analysis: Hidden Similarities and Differences, Journal of Computational Biology, vol.10, issue.6, pp.891-901, 2003. ,
DOI : 10.1089/106652703322756131
URL : http://biostats.bepress.com/cgi/viewcontent.cgi?article=1013&context=uwbiostat
Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome, Cancer Research, vol.70, issue.9, pp.3463-72, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-4213
Tissue-based map of the human proteome, Science, vol.42, issue.D1, p.1260419, 2015. ,
DOI : 10.1093/nar/gkt1140
Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes, Cell Reports, vol.9, issue.4, pp.1235-1280, 2014. ,
DOI : 10.1016/j.celrep.2014.10.035
Molecular pathways of urothelial development and bladder tumorigenesis, Urologic Oncology: Seminars and Original Investigations, vol.28, issue.4, pp.401-409, 2010. ,
DOI : 10.1016/j.urolonc.2009.04.019
Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871), Molecular Cancer Therapeutics, vol.12, issue.12, pp.2929-2968, 2013. ,
DOI : 10.1158/1535-7163.MCT-13-0442-T
Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers, Chinese Journal of Cancer, vol.31, issue.6, pp.266-80, 2012. ,
DOI : 10.5732/cjc.011.10405
IGF binding proteins in cancer: mechanistic and clinical insights, Nature Reviews Cancer, vol.52, issue.5, pp.329-370, 2014. ,
DOI : 10.1007/s10549-008-0046-x
IGF-binding protein-5: flexible player in the IGF system and effector on its own, Journal of Endocrinology, vol.172, issue.3, pp.423-463, 2002. ,
DOI : 10.1677/joe.0.1720423
IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder, Journal of Clinical Pathology, vol.14, issue.7, pp.573-82, 2013. ,
DOI : 10.1158/1078-0432.CCR-08-0408
A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.17, issue.19, pp.6304-6316, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-3336
Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.32, issue.19, pp.2059-66, 2014. ,
DOI : 10.1200/JCO.2013.54.4932
Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor, Clinical Cancer Research, vol.19, issue.15, pp.4282-4291, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-1840
Experimental models for therapeutic studies of transitional cell carcinoma, Anticancer Res, vol.27, issue.5A, pp.3163-71, 2007. ,